Hi King,
I can't be bothered with her anymore.
I was hoping that by myself and others, communicating with her all the issues and proven fallacies that she might have the humility to behave accordingly.
Instead she has proven that she is petty, and not only isn't editing the initial piece but has a feeling of "I'm gonna show them" mentality. Hilarious really.
So let her do as she wishes. After the initial piece I doubt the second one will have much of an impact.
This new piece is already wrong from the get go and just looking at her initial 4 key points. Her saying that Protalix products are me-too or bio-similar. Me-too or bio-similar would signify that the product is identical to the innovator product with the same onset of action, efficacy, duration of efficacy, and side effects.
This is obviously not the case with PRX-102, as these are all structurally different, the efficacy is far longer and thus also based on similar level of design to be resistant to degradation makes it's efficacy last much longer (40 times greater than leading market product Fabrazyme).
The EU would not have given it Orphan Drug designation if it were a me-too/bio-similar. Must show clinical meaningful difference and superiority for the Eu to have given PRX-102 the Orphan Drug Designation. More nonsense from this idiot.
Similarly for PRX-110, far longer activity and efficacy compared to market leading product Pulmozyme.
And for OPRX-106, this is clearly a completely novel way of delivering the market leading product (anti-TNF alpha), though an oral formulation, and with more direct administration to target site, with transient headaches and without systemic side-effects.
So no these are not me-too nor bio-similars, they are clearly superior.
If anything the level of similarity they do have with the current leading products is a boon for Protalix's products as these current leading products are the leading product because they have the buy in from clinicians, meaning their uptake will be that much easier.
She also says that the cost savings on production haven't helped for the Gaucher's sales. This is completely out of Protalix's hands as Pfizer is the one selling it and they are setting the price ludicrously high at something like 500,000 dollars. So again more nonsense, cause she doesn't understand the situation and it too immature to own up to it.
Constant drivel from this immature lady. If anything it's all quite sad really.
She can also leave it up as given the damage she assisted in before, most of the gullible people will have sold their positions. You can see that this article was published at 3:44pm ET, and looking at the stock price wasn't hit by it. Perhaps tomorrow we an see if there is a continued impact.
Anyway, now that we are aware of her character we know not to waste more time on her. Though I might write a tad bit, just because this nonsense shouldn't be allowed to continue without some rebuttal. Though I will most likely not waste too much energy on this.
